A secondary interpretation is needed on serum CA 125 levels in case of serosal involvement (multiple letters)
dc.authorscopusid | 7005479833 | |
dc.authorscopusid | 18838208900 | |
dc.authorscopusid | 57192870294 | |
dc.authorscopusid | 7004682700 | |
dc.authorscopusid | 7403429081 | |
dc.authorscopusid | 7203020108 | |
dc.authorscopusid | 57196502778 | |
dc.contributor.author | Sevinc A. | |
dc.contributor.author | Sari R. | |
dc.contributor.author | Carnei C. | |
dc.contributor.author | Buyukberber S. | |
dc.contributor.author | Ahmed A.S.M. | |
dc.contributor.author | Long M. | |
dc.contributor.author | Donaldson D. | |
dc.date.accessioned | 2024-08-04T20:02:25Z | |
dc.date.available | 2024-08-04T20:02:25Z | |
dc.date.issued | 2000 | |
dc.department | İnönü Üniversitesi | en_US |
dc.description.abstract | [No abstract available] | en_US |
dc.identifier.doi | 10.1177/146642400012000420 | |
dc.identifier.endpage | 270 | en_US |
dc.identifier.issn | 1466-4240 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 11197456 | en_US |
dc.identifier.scopus | 2-s2.0-0034536361 | en_US |
dc.identifier.scopusquality | N/A | en_US |
dc.identifier.startpage | 268 | en_US |
dc.identifier.uri | https://doi.org/10.1177/146642400012000420 | |
dc.identifier.uri | https://hdl.handle.net/11616/91663 | |
dc.identifier.volume | 120 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Journal of The Royal Society for the Promotion of Health | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | CA 125 antigen | en_US |
dc.subject | CA 19-9 antigen | en_US |
dc.subject | galactosyltransferase | en_US |
dc.subject | monoclonal antibody | en_US |
dc.subject | tumor marker | en_US |
dc.subject | ascites | en_US |
dc.subject | ascites fluid level | en_US |
dc.subject | blood level | en_US |
dc.subject | body weight disorder | en_US |
dc.subject | cancer diagnosis | en_US |
dc.subject | chronic kidney failure | en_US |
dc.subject | diagnostic value | en_US |
dc.subject | disease association | en_US |
dc.subject | hepatitis C | en_US |
dc.subject | human | en_US |
dc.subject | laparotomy | en_US |
dc.subject | letter | en_US |
dc.subject | nephrotic syndrome | en_US |
dc.subject | ovary cancer | en_US |
dc.subject | pancreas carcinoma | en_US |
dc.subject | pelvis tumor | en_US |
dc.subject | serosa | en_US |
dc.subject | uremia | en_US |
dc.subject | Aged | en_US |
dc.subject | Ascites | en_US |
dc.subject | CA-125 Antigen | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Weight Loss | en_US |
dc.title | A secondary interpretation is needed on serum CA 125 levels in case of serosal involvement (multiple letters) | en_US |
dc.type | Letter | en_US |